Grifols is anticipating a period of strong growth on the back of its recently FDA-approved intravenous immunoglobulin product Yimmugo ... has dropped the list of the next 15 drugs to be negotiated ...

Grifols SA engages in the production of plasma ... The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment ...

The list price of Tavlesse is £3,090 per 60 ... It was the first non-plasma product that the Grifols' flagship bioscience division launched in the European market. Grifols has filed for FDA ...